Cambridge, Massachusetts
United States
23
2020-10-15
19
2021-10-19
These are the the leading inventors for applications assigned to BIOGEN INC.:
BIOGEN INC. based in Cambridge, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Process for preparing spiro derivatives
#2 | 2020-08-27 ✅ Patent 11,192,856 granted on 2021-12-07Process for preparing alpha-carboxamide pyrrolidine derivatives
#3 | 2019-12-19 ✅ Patent 10,654,940 granted on 2020-05-19Method for treating joint damage
#4 | 2019-09-05 ✅ Patent 10,450,379 granted on 2019-10-22Method for treating joint damage
#5 | 2018-09-20TREATMENT OF AUTOIMMUNE DISEASES
#6 | 2018-05-03 ✅ Patent 10,400,043 granted on 2019-09-03Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
#7 | 2017-12-21 ✅ Patent 10,500,254 granted on 2019-12-10Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
#8 | 2016-11-17 ✅ Patent 10,113,000 granted on 2018-10-30Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
#9 | 2016-06-23 ✅ Patent 9,993,550 granted on 2018-06-12Treatment of pemphigus
#10 | 2016-04-14METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN
#11 | 2014-10-09 ✅ Patent 9,504,744 granted on 2016-11-29Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
#12 | 2012-10-11 ✅ Patent 9,296,821 granted on 2016-03-29Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodies
#13 | 2012-09-20 ✅ Patent 9,198,955 granted on 2015-12-01Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
#14 | 2010-10-14ANTIBODIES SPECIFICALLY REACTIVE WITH A TUMOR NECROSIS FACTOR RELATED LIGAND
#15 | 2010-08-05 ✅ Patent 9,493,567 granted on 2016-11-15Methods of treating inflammatory and autoimmune diseases with natalizumab
#16 | 2007-08-14 ✅ Patent 7,255,854 granted on 2007-08-14Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
#17 | 2007-02-08High expression locus vector based on ferritin heavy chain gene locus
#18 | 2007-02-06 ✅ Patent 7,173,046 granted on 2007-02-06CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications
#19 | 2006-09-26 ✅ Patent 7,112,665 granted on 2006-09-26Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants
#20 | 2006-04-18 ✅ Patent 7,030,080 granted on 2006-04-18Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
#21 | 2005-11-08 ✅ Patent 6,962,978 granted on 2005-11-08Polymer conjugates of interferon beta-1a and uses
#22 | 2005-04-05 ✅ Patent 6,875,743 granted on 2005-04-05Cell adhesion inhibitors
#23 | 2005-03-01 ✅ Patent 6,861,509 granted on 2005-03-01Antibodies to Ret and RetL3
Also check out BIOGEN INC.'s (Cambridge, United States) applicant profile with 8 patent applications submitted.
107033 ⎘